<DOC>
	<DOCNO>NCT02377895</DOCNO>
	<brief_summary>Single-center , double-masked , randomize , placebo-controlled , parallel-group , efficacy safety study use Allergen BioCube ( ABC ) .</brief_summary>
	<brief_title>Allergen Biocube Study Evaluating Efficacy Safety Nasapaque Nasal Solution Adult Subjects With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Key Must 18 year age provide write informed consent sign HIPAA form Must history allergic rhinitis Must positive response Allergen BioCube Key Must significant illness moderate severe allergic asthmatic reaction Must compromise lung function Must use disallow medication Must investigational study last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>